Hexarelin Acetate Research: GHS-R1a Pharmacology and Cardiac Biology

Hexarelin Acetate (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth hormone secretagogue representing the highest-potency compound in the GHRP research series. Developed through systematic structure-activity relationship studies of GHRP-6, Hexarelin incorporates a 2-methyltryptophan substitution at position 2 that dramatically increases GHS-R1a binding affinity — producing the highest peak GH release of any synthetic GHRP at equivalent molar concentrations.

Structural Basis for Increased Potency

The defining structural feature of Hexarelin is D-2-MeTrp at position 2, replacing the D-Trp2 of GHRP-6. Methylation of the indole nitrogen at the 2-position creates an N-methyl indole group that occupies the hydrophobic binding pocket of GHS-R1a with greater complementarity than the unmethylated tryptophan. This single modification produces approximately 3-5 fold increased binding affinity compared to GHRP-6 in competitive radioligand displacement assays using [125I]-ghrelin.

The hexapeptide backbone (6 residues versus GHRP-6's 6 and Ipamorelin's 5) positions the His1-D-2-MeTrp2 pharmacophore optimally for simultaneous engagement of the GHS-R1a orthosteric site and adjacent hydrophobic subsites. Comparative modelling of GHRP binding poses suggests Hexarelin achieves more complete occupation of the receptor binding cavity than shorter GHRPs, contributing to its superior potency.

GHS-R1a Pharmacology

GHS-R1a (growth hormone secretagogue receptor type 1a) is a class A GPCR coupling primarily through Gq/11 in pituitary somatotrophs. Hexarelin binding drives phospholipase C-beta activation, IP3-mediated calcium release from the ER, and DAG/PKC activation — the identical signalling cascade activated by all GHRPs and by the endogenous ligand ghrelin. The mechanistic distinction between Hexarelin and lower-potency GHRPs is quantitative, not qualitative: Hexarelin achieves greater receptor occupancy at a given concentration, producing a larger calcium transient and more complete GH secretory granule exocytosis.

The off-target profile of Hexarelin reflects its high potency across MCR subtypes and other GPCR targets. At concentrations producing near-maximal GH release, Hexarelin produces substantially more ACTH, cortisol, and prolactin stimulation than Ipamorelin or even GHRP-2. Research requiring GH axis stimulation without corticotroph or lactotroph activation should use Ipamorelin. Research specifically examining GHRP potency-selectivity trade-offs, or requiring maximal GHS-R1a occupancy, benefits from Hexarelin's high-affinity profile.

Comparative GHRP Research Design

The GHRP series (GHRP-6, GHRP-2, Hexarelin, Ipamorelin) provides a pharmacological toolkit spanning a wide range of GHS-R1a potency and selectivity. Research using all four compounds in parallel at matched molar concentrations maps the complete potency-selectivity landscape:

At equivalent molar doses in primary anterior pituitary cell preparations, the expected rank order for GH release is: Hexarelin > GHRP-2 > GHRP-6 ≈ Ipamorelin. For ACTH stimulation: Hexarelin > GHRP-6 > GHRP-2 >> Ipamorelin. For prolactin: GHRP-6 > Hexarelin > GHRP-2 >> Ipamorelin. These differential profiles across pituitary cell types directly map receptor selectivity differences between structurally related GHRPs.

Using this comparative framework, research can isolate the contribution of GHS-R1a binding affinity (Hexarelin versus Ipamorelin) from receptor selectivity (Ipamorelin's highly selective GHS-R1a versus Hexarelin's broader GPCR pharmacology) to observed biological outcomes in complex systems.

Cardiac Biology Research

Beyond GH axis pharmacology, published research has identified hexarelin binding sites on cardiomyocytes that are distinct from GHS-R1a. Bodart et al. and Torsello et al. published evidence that Hexarelin produces direct cardioprotective effects in ischaemia-reperfusion injury models that are not fully explained by GHS-R1a-mediated GH release. CD36 (fatty acid translocase, thrombospondin receptor) has been proposed as a cardiac hexarelin receptor that mediates GH-independent cardioprotective signalling.

Research examining this cardiac mechanism requires GHS-R1a blockade with a selective antagonist (such as [D-Lys3]-GHRP-6) during Hexarelin treatment. If cardioprotective effects persist despite GHS-R1a blockade, this supports the GH-independent cardiac mechanism hypothesis. CD36-dependence can be confirmed using CD36 knockdown (siRNA) or CD36-deficient cardiomyocyte models.

Cardioprotection research endpoints: lactate dehydrogenase (LDH) release as a membrane integrity marker in simulated ischaemia-reperfusion (37°C anoxia 60 minutes followed by reoxygenation 30 minutes); TUNEL staining for DNA fragmentation; phospho-Akt (Ser473) as a survival signalling readout; mitochondrial membrane potential by JC-1 staining; and cytochrome c release from mitochondria by ELISA of cytoplasmic fraction.

Research Applications

Primary pituitary cell GH secretion: isolate anterior pituitary cells by enzymatic digestion, density gradient purification, and plating at 100,000 cells/well. After 48-hour recovery, treat with Hexarelin (0.1nM-1µM) or vehicle. Collect medium at 15, 30, 60, and 120 minutes. Measure GH, ACTH, and prolactin in parallel from the same time-point samples. Calculate GH:ACTH and GH:prolactin selectivity ratios.

GHS-R1a calcium imaging: load GHS-R1a-HEK293 cells with Fura-2 AM (4µM, 45 minutes, 37°C). Measure ratiometric calcium signal (340/380nm excitation) during Hexarelin superfusion. Compare calcium transient amplitude, time-to-peak, and recovery kinetics with GHRP-2, GHRP-6, and Ipamorelin at matched EC50-equivalent concentrations.

Radioligand binding: incubate GHS-R1a membrane preparations with [125I]-ghrelin (0.1nM) and increasing Hexarelin concentrations (0.01nM-1µM). Non-specific binding determined by 1µM unlabelled ghrelin. Fit displacement curve to determine Ki by Cheng-Prusoff equation.

Key Published Research

• Deghenghi R, et al. "GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats." Life Sciences, 1994. PMID: 7968255
• Bodart V, et al. "CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart." Circulation Research, 2002. PMID: 11884375
• Torsello A, et al. "Hexarelin as a cardioprotective agent." Endocrine, 2003. PMID: 12963722

View Hexarelin Acetate →

For laboratory and analytical research purposes only. Not for human or veterinary use.